Cardioprotection – at the heart of long-term haemodialysis
The NEW FX CorDiax dialyser is designed to reduce the risks associated to cardiovascular disease in dialysis patients.The effects of chronic kidney disease (CKD) as well as the effects of dialysis itself can lead to cardiovascular diseases (e.g. atherosclerosis and left ventricular hypertrophy (LVH)), the largest causes of death in haemodialysis patients.1 Therefore the reduction of risk factors for cardiovascular diseases (CVD) is core to the development of dialysis systems and products at Fresenius Medical Care. Outstanding cardioprotection is reflected in all levels of product development and application.
Improved middle molecule removal, through enhanced High-Flux membranes for haemodiafiltration, can substantially reduce CVD risks.2 A number of large, multi-centre studies show that the use of High-Flux membranes improves patient survival and quality of life.3
The new FX CorDiax membrane offers access to the most efficient dialyser available within the FX-class family. Core to the success of the FX CorDiax is its Helixone® plus membrane. Advances in this fibre design and membrane porosity allow improved clearance of small molecular toxins as well as an improved removal of middle molecules represented by sieving coefficient for ß2-microglobulin (ß2-m) of 0.9. An increased level of serum ß2-m is associated with a higher mortality risk. The use of FX CorDiax dialysers in High-Flux dialysis or in ONLINE HDF facilitates the best possible therapy outcomes while minimising the loss of vital albumin.
Fresenius Medical Care will soon introduce this new dialyser range in an attempt to enhance clinical outcomes for all patients in Australia and New Zealand.
For more information about the new FX CorDiax dialyser or our new dialyser range, please contact us here.
- de Jager D. et al., JAMA (2009); 302: 1782-1789.
- Canaud B., Contrib Nephrol (2007); 158: 216-224.
- Locatelli F. et al., Journal of American Society of Nephrology (2009); 20: 645-654.